<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="361">
  <stage>Registered</stage>
  <submitdate>7/04/2003</submitdate>
  <approvaldate>7/04/2003</approvaldate>
  <nctid>NCT00058201</nctid>
  <trial_identification>
    <studytitle>Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer</studytitle>
    <scientifictitle>European Study Group For Pancreatic Cancer - Trial 3</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>RLUH-NCRI-ESPAC-3V2</secondaryid>
    <secondaryid>CDR0000287023</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pancreatic Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Pancreatic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - fluorouracil
Treatment: drugs - gemcitabine hydrochloride
Treatment: drugs - leucovorin calcium
Other interventions - clinical observation

Active Comparator: Arm I - Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.

Experimental: Arm II - Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.

No Intervention: Arm III - Patients undergo observation.


Treatment: drugs: fluorouracil
Given IV

Treatment: drugs: gemcitabine hydrochloride
Given IV

Treatment: drugs: leucovorin calcium
Given IV

Other interventions: clinical observation
No intervention

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity as measured by NCI CTC v2.0</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life as measured by EORTC QLQ C-30 and ESPAC-QLQ at 3, 6, and 12 months, and then annually for 5 years</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Survival rate at 2 and 5 years</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed ductal adenocarcinoma of the pancreas OR

          -  Histologically confirmed diagnosis of 1 of the following types of cancer:

               -  Acinar cell carcinoma or cystadenocarcinoma of the pancreas

               -  Cancers of the periampullary region

               -  Cancers of the intrapancreatic part of the bile duct

               -  Periampullary cancers of uncertain origin

          -  Complete macroscopic resection (R0 or R1 resection)

               -  Histological examination of all resection margins required

          -  No stage IVB disease

          -  No evidence of malignant ascites

          -  No liver or peritoneal metastases

          -  No evidence of spread to other distant abdominal or extra-abdominal organs

          -  No pancreatic lymphoma

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  More than 3 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant

          -  Able to participate in long-term follow-up

          -  No other prior or concurrent malignancy except curatively treated basal cell skin
             cancer or carcinoma in situ of the cervix

          -  No serious medical or psychological condition that would preclude study treatment

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No neoadjuvant chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics

          -  Recovered from prior resection</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1030</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA</recruitmentstate>
    <hospital>Institute of Oncology at Prince of Wales Hospital - Randwick</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <postcode>2031 - Randwick</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Preha 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gydr</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Verona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Bern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Royal Liverpool University Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>NCIC Clinical Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australasian Gastro-Intestinal Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. It is not yet known which chemotherapy regimen is more effective,
      or whether chemotherapy is more effective than observation, in treating pancreatic cancer
      after surgery.

      PURPOSE: Phase III trial to compare the effectiveness of two chemotherapy regimens with no
      further therapy in treating patients who have completely resected pancreatic cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00058201</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>John P. Neoptolemos, MD</name>
      <address>Royal Liverpool University Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>